How can a patient check whether commercial insurance covers GLP-1 treatment for obesity in 2026?

To check if your insurance covers GLP-1s for obesity, review your plan's drug formulary, understand its prior authorization rules, and call to confirm.

Start with Your Plan's Drug Formulary

Your insurance plan's drug formulary is the official list of prescription drugs it covers. This document is the first place to check for GLP-1 medications indicated for weight management, such as Wegovy (semaglutide) or Zepbound (tirzepatide). Formularies are typically organized into tiers, which determine your copayment or coinsurance amount.

You can usually find the formulary by logging into your insurer's online member portal. Look for a section called "Prescription Coverage," "Drug List," or "Pharmacy Benefits." Use the search function to look for the specific brand name of the medication. Do not search for "semaglutide" or "tirzepatide" alone, as coverage often depends on the brand and its FDA-approved indication.

The presence of a drug on the formulary does not guarantee coverage. Look for codes next to the drug name. "PA" means Prior Authorization is required, "QL" indicates Quantity Limits (e.g., one pen per month), and "ST" means Step Therapy is necessary, requiring you to try and fail other, less expensive treatments first.

Navigating Prior Authorization for Obesity Medications

Prior Authorization (PA) is a process used by insurance companies to verify that a prescribed medication is medically necessary. For GLP-1s used in obesity treatment, a PA is almost always required. Your physician must submit clinical documentation to the insurer for review before the prescription can be filled and covered.

Insurers have specific clinical criteria for approving GLP-1s for chronic weight management. Typically, a patient must have a Body Mass Index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity like hypertension or high cholesterol. Plans may also require proof of participation in a comprehensive lifestyle program.

Your physician's office handles the PA submission. They will compile your relevant medical history, chart notes, and lab results to demonstrate to the insurer that you meet their criteria. An approval is usually valid for a set period, such as 6 or 12 months, after which a re-authorization may be needed to continue treatment.

Your Checklist for Verifying GLP-1 Coverage

Step 1: Access your plan's formulary through your insurer's online portal. Search for the specific brand names (Wegovy, Zepbound) to see if they are listed as a covered benefit.

Step 2: Note the drug's tier and any associated restrictions like Prior Authorization (PA), Quantity Limits (QL), or Step Therapy (ST). This will give you a clear picture of the initial requirements and potential out-of-pocket costs.

Step 3: Call the member services number on your insurance card. Ask the representative directly: "Is [drug name] covered for the indication of chronic weight management under my plan?" and "What are the specific clinical criteria for the prior authorization process?"

Step 4: Schedule a consultation with your doctor to discuss your findings. Your physician can determine if you are a good candidate for a physician-supervised [weight-loss](/weight-loss) program and if you meet the insurer's established criteria. If so, they can initiate the PA request on your behalf.

The Changing Landscape of Obesity Care Coverage

While this process is current, the insurance landscape for 2026 is expected to continue evolving. A growing number of employers are opting to include anti-obesity medications (AOMs) in their health plans, recognizing obesity as a chronic disease requiring medical treatment. However, the high cost of these drugs remains a significant barrier to broader coverage.

Coverage for AOMs is determined by the employer who sponsors the health plan, not the insurance company itself. Therefore, coverage can vary dramatically even among patients who have the same insurer but different employers. These decisions are typically made annually.

Legislation could also influence future coverage. For example, the Treat and Reduce Obesity Act (TROA), if passed, would expand Medicare coverage for AOMs. While this bill applies to Medicare, it could influence coverage trends among commercial plans by signaling a shift in federal policy toward recognizing obesity treatment as essential.

Because formularies and employer-sponsored benefits change each year, it is essential to re-verify your coverage annually during your open enrollment period. A medication covered in 2025 may have different restrictions or may not be covered at all in 2026.

What to Do If Coverage Is Denied

If your request for a GLP-1 medication is denied, the first step is to understand why. Your insurer will provide an Explanation of Benefits (EOB) or a formal denial letter that outlines the reason, which could be a formulary exclusion or a failure to meet PA criteria.

You and your physician have the right to appeal the decision. The appeals process typically involves submitting a letter of medical necessity, along with additional clinical evidence supporting the need for the treatment. Appeals can sometimes be successful, especially if the initial denial was based on incomplete information.

If the medication is not on your plan's formulary, discuss alternatives with your doctor. Other classes of weight management medications may be covered. For eligible patients with commercial insurance, manufacturer savings programs or copay cards may also be available to reduce out-of-pocket costs, though they do not guarantee coverage.

Bottom Line

Verifying if your commercial insurance plan will cover a GLP-1 medication for obesity in 2026 involves a multi-step investigation: reviewing the drug formulary, understanding the prior authorization criteria, and directly communicating with your insurer.

Coverage is highly variable and depends entirely on the benefits your employer has chosen to include in your plan. While the trend is toward greater acceptance of anti-obesity medications, their high list price means access will likely remain a challenge for many.

This article is for informational purposes only and is not medical advice. Always consult a licensed healthcare professional for diagnosis and treatment.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.